Trust Signals
Evidence standard: Every major claim is graded in the evidence ledger below. Speculative claims are labeled as such.
Conflicts of interest: FormBlends sells research compounds. We disclose this and have written this page to reflect the evidence honestly, including where the data is weak or where alternatives outperform peptides.
Last updated: May 29, 2026.
Key Takeaways
Direct Answer: GHRP-2 vs Ipamorelin in 50 Words
GHRP-2 and ipamorelin are both GHSR-1a agonists that trigger GH pulses. GHRP-2 hits harder but also raises cortisol and prolactin. Ipamorelin delivers selective GH stimulation with a cleaner hormonal fingerprint. For most research applications where isolated GH axis activation is the goal, ipamorelin's selectivity is the practical advantage.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- Evidence Ledger: What the Research Actually Supports
- Mechanism with Specific Numbers
- What Are the Real Side Effect Differences?
- What Most Pages Get Wrong About GHRP-2 vs Ipamorelin
- Why the Chemistry Rules Matter: Stability and Formulation
- Honest Head-to-Head Comparison Table
- How Do Both Compare to Approved Alternatives?
- Operational Dosing and Label Literacy
- Does Combining Them Make Sense?
- Frequently Asked Questions
- Sources
Evidence Ledger: What the Research Actually Supports
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| GHRP-2 stimulates GH release in humans | Human clinical studies, multiple groups | Positive, robust | High |
| Ipamorelin stimulates GH release | Animal studies (Raun 1998), limited human data | Positive | Moderate |
| GHRP-2 raises cortisol and ACTH | Human clinical studies (Arvat et al., multiple) | Positive (undesired) | High |
| Ipamorelin does NOT raise cortisol at GH-stimulating doses | Animal studies (Raun 1998); limited human corroboration | Neutral (desired) | Moderate (animal), Low (human) |
| GHRP-2 raises prolactin | Human clinical studies | Positive (undesired) | High |
| Either peptide improves body composition in humans | No published human RCT for either compound | Unproven in humans | Very Low |
| GH pulse magnitude is larger with GHRP-2 vs ipamorelin at equivalent doses | Animal comparative data; no direct human RCT | GHRP-2 likely greater | Low |
| Both have short plasma half-lives (minutes range) | Pharmacokinetic inference and limited PK data | Consistent with pulsatile GH pattern | Moderate |
| Desensitization occurs with frequent GHRP-2 dosing | Animal receptor downregulation data | Positive (undesired) | Low (in humans) |
Mechanism with Specific Numbers
Shared receptor: Both peptides are agonists at growth hormone secretagogue receptor 1a (GHSR-1a), a G-protein coupled receptor expressed densely in the pituitary and hypothalamus. Activation of GHSR-1a triggers intracellular calcium mobilization and protein kinase C signaling, which drives GH granule exocytosis from somatotroph cells.
GHRP-2 structure and broader activity: GHRP-2 is a synthetic hexapeptide (D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) with high GHSR-1a binding affinity. It also has documented activity at CD36, a scavenger receptor involved in fatty acid uptake and inflammatory signaling. This off-target binding is the likely contributor to its cortisol and ACTH co-secretion, as it stimulates the hypothalamic-pituitary-adrenal axis in addition to the GH axis. Arvat and colleagues at the University of Turin published multiple studies in the late 1990s documenting significant ACTH, cortisol, and prolactin rises alongside GH after GHRP-2 administration in healthy human subjects.
Ipamorelin structure and selective design: Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed by Novo Nordisk and published by Raun et al. in 1998 in the European Journal of Endocrinology. The Raun 1998 study compared ipamorelin head-to-head with GHRP-2 and GHRP-6 in rats and found that at doses producing equivalent GH release, ipamorelin caused no statistically significant increase in cortisol or prolactin, while GHRP-2 and GHRP-6 produced significant elevations of both. The structural modifications were designed to improve GHSR-1a selectivity and reduce interaction with receptors driving the adrenal and lactotroph responses.
What the mechanism does NOT prove: A clean cortisol fingerprint in a rat model does not confirm that ipamorelin is safe or effective for any human indication. The mechanism explains why ipamorelin was designed the way it was, but human long-term data on either peptide is absent from the published literature.
What Are the Real Side Effect Differences?
| Side Effect | GHRP-2 | Ipamorelin | Confidence in Difference |
|---|---|---|---|
| Cortisol elevation | Documented in humans | Minimal to none at standard doses (animal data) | Moderate |
| Prolactin elevation | Documented in humans | Minimal to none (animal data) | Moderate |
| Hunger / appetite stimulation | Plausible (ghrelin receptor agonism) | Plausible (same mechanism) | Low (no head-to-head quantification) |
| Water retention / edema | Possible, class effect of GH elevation | Possible, same class effect | Very Low |
| Injection site irritation | Reported anecdotally | Reported anecdotally | Very Low |
| Receptor desensitization with chronic use | Documented in animal models | Less data, likely similar | Very Low (human) |
What Most Pages Get Wrong About GHRP-2 vs Ipamorelin
The pulse size framing is misleading. Most comparison pages present the larger GHRP-2 GH pulse as straightforwardly "better." They omit that a larger GH pulse accompanied by a cortisol spike is not equivalent to a similar-magnitude clean GH pulse. Cortisol is catabolic and lipolysis-blunting in the context of chronic elevation. The co-secretion issue is not a minor footnote; it changes the hormonal calculus meaningfully.
The "selectivity" claim for ipamorelin is often overclaimed too. The Raun 1998 paper is an animal study. There is no large, well-powered human pharmacodynamic study confirming that ipamorelin produces zero cortisol or prolactin rise in every human at every dose. "Selective in rats" is not the same as "completely cortisol-neutral in humans at all doses." This distinction matters for honest communication.
Desensitization is almost never discussed. GHSR-1a undergoes receptor internalization and downregulation with repeated agonist exposure. This is a well-established feature of GPCR biology. With frequent or chronic GHRP dosing, the GH response to each injection is likely to attenuate over time. No long-term human dose-response desensitization study exists for either peptide, but the mechanism is real and users relying on twice-daily or three-times-daily injection schedules indefinitely are working against basic receptor pharmacology.
Purity and sourcing are the elephant in the room. Because neither peptide is pharmaceutical-grade with FDA approval, the peptide powders circulating in research and gray markets vary widely in purity. A certificate of analysis (COA) from a third-party HPLC and mass spectrometry lab is the minimum standard for knowing what is actually in a vial. Commodity pages never discuss this. A 90% pure peptide behaves differently than a 98% pure peptide, and impurities in injectable-grade products carry safety implications that are not theoretical.
Why the Chemistry Rules Matter: Stability and Formulation
Why lyophilized powder is stored cold: Both GHRP-2 and ipamorelin are short peptides prone to hydrolysis and oxidation. In lyophilized (freeze-dried) form, removing water slows hydrolytic cleavage of peptide bonds dramatically. Heat accelerates the Arrhenius-governed degradation rate. Storing lyophilized peptide at room temperature rather than 2 to 8 degrees Celsius is not merely precautionary: it meaningfully shortens usable shelf life, though the precise rate constant for each peptide at various temperatures is not published in accessible literature.
Why reconstituted solutions degrade faster: Once reconstituted in bacteriostatic water, the peptide is now in aqueous solution where hydrolysis can proceed. The benzyl alcohol preservative in bacteriostatic water slows microbial growth but does not stop peptide degradation. Repeated freeze-thaw cycles of reconstituted solution stress the peptide structurally and accelerate aggregation. Best practice is to reconstitute in the volume needed for a defined period (commonly cited as roughly 2 to 4 weeks refrigerated) and keep freeze-thaw cycles to a minimum.
Why light exposure matters: The aromatic residues in both peptides (tryptophan in GHRP-2, naphthylalanine in both) are susceptible to photo-oxidation under UV exposure. This is why amber or opaque vials and dark storage are not arbitrary preferences but reflect real photochemical degradation pathways.
What degraded product looks like: A fresh reconstituted solution should be clear and colorless to very slightly off-white. Cloudiness, visible particulates, or yellowish discoloration in the solution are signs of degradation or contamination. Lyophilized powder that has yellowed, clumped into a wet cake, or partially collapsed from white powder suggests heat or moisture exposure. Degraded product should not be used, as the breakdown peptide fragments have unknown biological activity.
Honest Head-to-Head Comparison Table
| Parameter | GHRP-2 | Ipamorelin | Winner / Caveat |
|---|---|---|---|
| Primary receptor | GHSR-1a (plus off-targets including CD36) | GHSR-1a (selective) | Ipamorelin (selectivity) |
| GH pulse magnitude | Likely larger at equivalent doses | Moderate | GHRP-2, but context-dependent |
| Cortisol co-secretion | Documented elevation in humans | Minimal in animal models | Ipamorelin (clearly) |
| Prolactin co-secretion | Documented elevation in humans | Minimal in animal models | Ipamorelin (clearly) |
| Human body composition RCT data | None published | None published | Neither; both very low evidence |
| FDA approval status | Not approved | Not approved | Neither |
| Research literature depth | More published clinical PD studies | Less human data, key animal study strong | GHRP-2 (more human PD data) |
| Appetite stimulation risk | Present (GHSR-1a ghrelin mimetic) | Present (same mechanism) | Neither wins; tied |
How Do Both Compare to Approved Alternatives?
| Compound | Approval Status | GH Axis Evidence Quality | Major Limitation |
|---|---|---|---|
| Sermorelin (GHRH analog) | Previously FDA-approved (withdrawn commercially, compounded) | Human clinical trials | Weaker GH pulse alone vs. GHRP combination |
| Recombinant human GH (rhGH, e.g., somatropin) | FDA-approved for specific indications | Extensive human RCT data | Supraphysiologic IGF-1 risk, cost, requires diagnosis |
| Tesamorelin | FDA-approved (HIV-associated lipodystrophy) | Multiple human RCTs | Narrow indication; not approved for general use |
| GHRP-2 | Not approved | Human pharmacodynamic studies; no RCT for outcomes | Cortisol and prolactin co-secretion |
| Ipamorelin | Not approved | Animal selectivity study; limited human data | Weakest human evidence base of this group |
The honest takeaway: recombinant human GH and tesamorelin have far more robust evidence than either GHRP. If a physician determines GH axis intervention is clinically appropriate, those approved options represent a much higher evidence standard. GHRP-2 and ipamorelin are research compounds, not substitutes for approved therapies.
Operational Dosing and Label Literacy
Research dose context: GHRP-2 has been administered in human pharmacodynamic studies most commonly at 1 microgram per kilogram intravenously or subcutaneously. Ipamorelin has been studied in animals and in limited human data at roughly 1 to 3 micrograms per kilogram subcutaneously. These figures describe research protocols, not prescribing recommendations.
Reconstitution math example: A 5 mg lyophilized vial reconstituted with 2.5 mL of bacteriostatic water yields a concentration of 2 mg per mL (2000 micrograms per mL). A 100 microgram research dose would be 0.05 mL on a standard insulin syringe. Always calculate based on the specific vial size and reconstitution volume provided; do not assume a standard concentration.
How to read a COA: A valid certificate of analysis for a research peptide should include: identity confirmation by mass spectrometry (the molecular weight should match the theoretical value for the peptide sequence), purity by HPLC (look for greater than 98% purity for injectable research use), a batch or lot number, and a testing date. A COA without MS confirmation or with purity listed only by supplier without third-party testing is insufficient. If the seller cannot produce a third-party COA on request, that is a disqualifying red flag.
Does Combining GHRP-2 and Ipamorelin Make Sense?
Some research protocols pair a GHRH analog (CJC-1295, sermorelin) with a GHRP (ipamorelin or GHRP-2) because GHRH and GHRPs act through distinct receptor systems that are synergistic. Combining the two classes amplifies GH release more than either alone.
Combining GHRP-2 with ipamorelin, however, pairs two compounds acting on the same receptor (GHSR-1a). This does not produce meaningful pharmacological synergy and would simply double the cortisol and selectivity tradeoffs of GHRP-2 without a clear mechanistic benefit over ipamorelin alone. This combination is not a standard research design and is not supported by published literature as superior to either peptide used with a GHRH analog.
Frequently Asked Questions
What is the main difference between GHRP-2 and ipamorelin?
GHRP-2 is a hexapeptide that stimulates GH release but also meaningfully raises cortisol and prolactin. Ipamorelin is a pentapeptide that produces selective GH release with minimal to no cortisol or prolactin elevation at standard doses. Ipamorelin's selectivity makes its side effect profile more favorable for most research applications.
Does GHRP-2 raise cortisol more than ipamorelin?
Yes. Multiple clinical studies document GHRP-2 producing statistically significant cortisol and ACTH elevations alongside GH release. Ipamorelin was specifically designed to avoid this. Raun et al. (1998) found no significant cortisol or prolactin rise at GH-stimulating doses in animal models, a selectivity profile that represents ipamorelin's main design advantage.
Which peptide produces a stronger GH pulse, GHRP-2 or ipamorelin?
GHRP-2 generally produces a larger acute GH pulse at equivalent microgram doses. However, ipamorelin's cleaner hormonal profile means it is often preferred when the research goal is isolated GH axis stimulation without confounding cortisol or prolactin co-secretion.
What is the typical research dose for GHRP-2 and ipamorelin?
In human clinical research, GHRP-2 has been studied most often at 1 microgram per kilogram administered intravenously or subcutaneously. Ipamorelin has been studied at doses ranging from roughly 1 to 3 micrograms per kilogram subcutaneously. These are research-context figures, not clinical prescribing recommendations.
Can GHRP-2 and ipamorelin be combined?
Combining two GHRPs acting on the same receptor does not produce meaningful synergy. The productive combination strategy in research is pairing a GHRH analog (CJC-1295, sermorelin) with a single GHRP, because those two classes act on distinct receptor systems. Combining GHRP-2 and ipamorelin is not a standard or evidence-backed protocol.
What receptor do GHRP-2 and ipamorelin act on?
Both are agonists at GHSR-1a, the ghrelin receptor. GHRP-2 also has documented off-target activity at CD36 and other receptors that may contribute to its broader endocrine effects. Ipamorelin was optimized for GHSR-1a selectivity, which is the structural basis for its differentiated hormonal profile.
How long is the half-life of GHRP-2 and ipamorelin?
Both peptides have short plasma half-lives estimated in the tens of minutes range for subcutaneous administration, which is why they produce a pulsatile GH spike rather than sustained elevation. Precise, well-powered human pharmacokinetic data is limited in the published literature for both compounds.
Does ipamorelin cause hunger or increased appetite?
Appetite stimulation is a plausible on-target effect because GHSR-1a is also the receptor for ghrelin, a hunger-signaling hormone. Anecdotal reports for both peptides mention mild hunger increases. Neither compound has been robustly quantified in controlled human appetite studies.
Are GHRP-2 and ipamorelin FDA approved?
No. Neither is FDA-approved as a drug. Both are investigational research compounds. The FDA has flagged numerous growth hormone secretagogue peptides in warning letters to compounding pharmacies, and use outside supervised research or compounding with appropriate oversight carries regulatory and safety risk.
How should GHRP-2 and ipamorelin peptides be stored?
Lyophilized powder should be stored at 2 to 8 degrees Celsius and protected from light. Once reconstituted in bacteriostatic water, solutions should be refrigerated and are generally usable for roughly 2 to 4 weeks depending on conditions and handling. Repeated freeze-thaw cycles accelerate degradation.
Which peptide is better for body composition research?
No head-to-head human RCT comparing the two for body composition outcomes exists. Most researchers prefer ipamorelin for body composition protocols because its selective GH release avoids the cortisol elevation GHRP-2 produces. Chronic cortisol elevation is catabolic and can counteract desired anabolic and lipolytic effects.
What does a degraded peptide vial look like?
A degraded solution may appear cloudy, have visible particulates, or show yellowish discoloration compared to a clear or slightly off-white fresh solution. Lyophilized powder that has yellowed or clumped may have been exposed to heat or moisture. Degraded product should not be used.
Sources
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998;139(5):552-561.
- Arvat E, Di Vito L, Broglio F, et al. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. Journal of Endocrinological Investigation. 2000;23(8):493-495.
- Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1169-1174.
- Bowers CY. Growth hormone-releasing peptides: history and mechanisms of action. In: Ghigo E, Boghen M, Casanueva FF, Dieguez C, eds. Growth Hormone Secretagogues. Elsevier Science; 1999.
- Smith RG. Development of growth hormone secretagogues. Endocrine Reviews. 2005;26(3):346-360.
- Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.
- Frohman LA, Kineman RD. Growth hormone-releasing hormone and pituitary development, hyperplasia and tumorigenesis. Trends in Endocrinology and Metabolism. 2002;13(7):299-303.
- U.S. Food and Drug Administration. FDA warns companies to stop selling injectable drug products containing growth hormone-releasing peptides. FDA Safety Communication. Published 2023. Available at fda.gov.
- Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides. European Journal of Endocrinology. 1997;136(5):445-460.
- Veldhuis JD, Bowers CY. Human GH pulsatility: an ensemble property regulated by age and gender. Journal of Endocrinological Investigation. 2003;26(9):799-813.